Gerelsaikhan Tudevdagva, Chen Xiao-Liang, Chander Avinash
Department of Pediatrics, Stony Brook University Medical Center, Stony Brook, NY 11794, USA.
Biochim Biophys Acta. 2011 Dec;1813(12):2017-25. doi: 10.1016/j.bbamcr.2011.07.022. Epub 2011 Sep 2.
Membrane fusion between the lamellar bodies and plasma membrane is an obligatory event in the secretion of lung surfactant. Previous studies have postulated a role for annexin A7 (A7) in membrane fusion during exocytosis in some cells including alveolar type II cells. However, the intracellular trafficking of A7 during such fusion is not described. In this study, we investigated association of endogenous A7 with lamellar bodies in alveolar type II cells following treatment with several secretagogues of lung surfactant. Biochemical studies with specific antibodies showed increased membrane-association of cell A7 in type II cells stimulated with agents that increase secretion through different signaling mechanisms. Immuno-fluorescence studies showed increased co-localization of A7 with ABCA3, the lamellar body marker protein. Because these agents increase surfactant secretion through activation of PKC and PKA, we also investigated the effects of PKC and PKA inhibitors, bisindolylmaleimideI (BisI) and H89, respectively, on A7 partitioning. Western blot analysis showed that these inhibitors prevented secretagogue-mediated A7 increase in the membrane fractions. These inhibitors also blocked increased co-localization of A7 with ABCA3 in secretagogue-treated cells, as revealed by immuno-fluorescence studies. In vitro studies with recombinant A7 showed phosphorylation with PKC and PKA. The cell A7 was also phosphorylated in cells treated with surfactant secretagogues. Thus, our studies demonstrate that annexin A7 relocates to lamellar bodies in a phosphorylation-dependent manner. We suggest that activation of protein kinase promotes phosphorylation and membrane-association of A7 presumably to facilitate membrane fusion during lung surfactant secretion.
板层小体与质膜之间的膜融合是肺表面活性物质分泌过程中的一个必要事件。先前的研究推测,膜联蛋白A7(A7)在包括肺泡II型细胞在内的一些细胞的胞吐作用的膜融合过程中发挥作用。然而,在此类融合过程中A7的细胞内运输情况尚无描述。在本研究中,我们在用几种肺表面活性物质促分泌剂处理后,研究了肺泡II型细胞中内源性A7与板层小体的关联。用特异性抗体进行的生化研究表明,通过不同信号机制增加分泌的试剂刺激II型细胞后,细胞A7的膜结合增加。免疫荧光研究表明,A7与板层小体标记蛋白ABCA3的共定位增加。由于这些试剂通过激活蛋白激酶C(PKC)和蛋白激酶A(PKA)来增加表面活性物质的分泌,我们还分别研究了PKC和PKA抑制剂双吲哚马来酰亚胺I(BisI)和H89对A7分配的影响。蛋白质印迹分析表明,这些抑制剂可阻止促分泌剂介导的A7在膜组分中的增加。免疫荧光研究显示,这些抑制剂还可阻断促分泌剂处理细胞中A7与ABCA3共定位的增加。用重组A7进行的体外研究表明,A7可被PKC和PKA磷酸化。在用表面活性物质促分泌剂处理的细胞中,细胞A7也发生了磷酸化。因此,我们的研究表明,膜联蛋白A7以磷酸化依赖的方式重新定位于板层小体。我们认为,蛋白激酶的激活促进了A7的磷酸化和膜结合,大概是为了在肺表面活性物质分泌过程中促进膜融合。